Exchange: NASDAQ·Updated 07:30 PM EST

CLDX News

News
all
press releases
Celldex Therapeutics (NASDAQ:CLDX) Price Target Cut to $50.00 by Analysts at Barclays
Barclays dropped their target price on Celldex Therapeutics from $53.00 to $50.00 and set an "overweight" rating on the stock in a research report on Friday...
MarketBeat
Celldex Therapeutics (NASDAQ:CLDX) Price Target Cut to $50.00 by Analysts at Barclays
Barclays dropped their target price on Celldex Therapeutics from $53.00 to $50.00 and set an "overweight" rating on the stock in a research report on Friday...
MarketBeat
More News
HC Wainwright lowered their target price on shares of Celldex Therapeutics from $64.00 to $58.00 and set a "buy" rating on the stock in a report on Friday...
MarketBeat
(RTTNews) - Celldex Therapeutics, Inc. (CLDX) on Thursday stated it is discontinuing development of barzolvolimab in atopic dermatitis (AD) after the Phase 2 trial missed its primary and secondary endpoints...
Nasdaq News: Markets
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Celldex Therapeutics, Inc. (NASDAQ: CLDX) SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Celldex Therapeutics, Inc. (NASDAQ: CLDX)PR NewswireNEW YORK, Oct. 12, 2026NEW YORK, Oct. 12...
PR Newswire
Four biotech companies face key fall readouts that could influence the development and commercial prospects of their pipelines.
Zacks
H.C. Wainwright called the Phase 3 results a “compelling” late-stage assessment of Barzolvolimab in a patient population with a significant unmet need.
Stocktwits
KOD, CLDX, RAPP and PCVX face key clinical readouts this fall that could influence their drug and vaccine pipelines.
Zacks
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Celldex Therapeutics, Inc. (NASDAQ: CLDX) SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Celldex Therapeutics, Inc. (NASDAQ: CLDX) PR Newswire NEW YORK, Aug. 24, 2026 NEW YORK, Aug...
PR Newswire
Celldex (CLDX) delivered earnings and revenue surprises of +9.62% and -98.75%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Here is how Celldex Therapeutics (CLDX) and Illumina (ILMN) have performed compared to their sector so far this year.
Zacks

Advertisement|Remove ads.